SPAGO — Spago Nanomedical AB (publ) Income Statement
0.000.00%
- SEK75.21m
- SEK42.74m
- SEK1.91m
Annual income statement for Spago Nanomedical AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.342 | 0.66 | 1.05 | 1.2 | 1.91 |
Cost of Revenue | |||||
Gross Profit | 6.11 | 4.92 | 4.75 | — | — |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19.3 | 39.9 | 40.5 | 44.3 | 35.6 |
Operating Profit | -19 | -39.2 | -39.5 | -43.1 | -33.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.9 | -39.1 | -39.2 | -42.2 | -32.5 |
Net Income After Taxes | -18.9 | -39.1 | -39.2 | -42.2 | -32.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.9 | -39.1 | -39.2 | -42.2 | -32.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.9 | -39.1 | -39.2 | -42.2 | -32.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.653 | -0.934 | -0.587 | -0.431 | -0.11 |
Dividends per Share |